Browsing Tag

HCM

New scanning methods can detect deadly heart condition before symptoms appear: Combining two types…

Jason Junior Jul 23, 2023

Combining two types of heart scan techniques could help doctors to detect the deadly heart condition hypertrophic cardiomyopathy (HCM) before symptoms and signs on conventional tests appear, according to a new study led by UCL researchers.…

Technology

HCM trends and pain points – time to get back to basics? (webinar)

Amelia Podder May 16, 2023

Thursday 15 June 2023, 2:00pm BST The HR professional’s role has never been more challenging. Skills shortages, growth in employee expectations and developments in artificial intelligence and automation have made talent management harder…

Health

Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions…

Jason Junior Sep 26, 2022

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two presentations at the 2022 Inaugural HCM Society Scientific Sessions, held…

Health

Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society…

Jason Junior Jun 4, 2022

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in…

Health

U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with…

Jason Junior Apr 29, 2022

SHANGHAI and PRINCETON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10…

Health

Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of…

Jason Junior Apr 2, 2022

SOUTH SAN FRANCISCO, Calif., April 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive…

Health

Obstructive HCM: Will Septal Reduction Zapping Hold Up?

Jason Junior Mar 30, 2022

Operators continued to make progress on an investigational septal reduction procedure for drug-refractory obstructive hypertrophic cardiomyopathy…

Health

Paycor Enhances HCM Solution with New Immunization Tracker

Jason Junior Sep 22, 2021

CINCINNATI, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Paycor HCM, Inc. (Paycor) (Nasdaq: PYCR) today announced an enhancement to their HCM solution—an Immunization Tracker that helps business leaders manage and track the immunization status of…

Health

Second-Gen Drug for HCM Emerges, Nipping at Mavacamten’s Heels

Jason Junior Sep 13, 2021

A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding…

Health

A Familiar Drug Can Keep Early-Stage HCM at Bay

Jason Junior Aug 28, 2021

People genetically predisposed to hypertrophic cardiomyopathy (HCM) could slow down their disease progression by taking an inexpensive, widely available medication, the VANISH trial…